Products

Online Inquiry

Name

Email *

Phone *

Company/Institution

Country or Region

Quantity

Services & Products Interested *

Project Description

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Ruxolitinib (INCB018424)

inquiry

Cat No.

CEI-0187

Description

Ruxolitinib (INCB018424) can inhibit JAK1, JAK2 and JAK3 with IC50 of 3 nM, 5 nM and 332 nM.

CAS No.

941678-49-5

Molecular Weight

306.37

Purity

>99%

Storage

2 years at -20centigrade Powder

Targets

Jak1, Jak2, Jak3

Molecular Formula

C17H18N6

Chemical Name

(3R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

Solubility

DMSO 61 mg/mL Water

In vitro

Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, and INCB018424 (Ruxolitinib) inhibit Jak1, Jak2, and Jak3 with IC50 of 3 nM, 5 nM and 332 nM, respectively. Ruxolitinib (INCB-018424) is developed to target the constitutive activation of the JAK-STAT pathway in patients with myeloproliferative neoplasms (MPNs). Ruxolitinib (Jakafi; Incyte) is a small-molecule inhibitor of JAK1/2 that has proved to be effective at reducing splenomegaly and ameliorating symptoms in myeloproliferative neoplasms.